Published in Front Immunol on December 13, 2013
Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016) 1.31
Cancer vaccines. BMJ (2015) 1.07
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget (2015) 0.92
Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models. Front Immunol (2015) 0.91
Dendritic cell-based vaccine efficacy: aiming for hot spots. Front Immunol (2015) 0.89
Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma. J Clin Cell Immunol (2015) 0.84
Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Genome Med (2014) 0.82
Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses. Oncotarget (2016) 0.79
Antigenically Modified Human Pluripotent Stem Cells Generate Antigen-Presenting Dendritic Cells. Sci Rep (2015) 0.79
Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme. Biomed Res Int (2015) 0.78
Dendritic cell-based therapeutic cancer vaccines: past, present and future. Clin Exp Vaccine Res (2014) 0.78
An optimized peptide vaccine strategy capable of inducing multivalent CD8(+) T cell responses with potent antitumor effects. Oncoimmunology (2015) 0.78
Impact of the prolymphangiogenic crosstalk in the tumor microenvironment on lymphatic cancer metastasis. Biomed Res Int (2014) 0.77
Dendritic cell vaccines containing lymphocytes produce improved immunogenicity in patients with cancer. J Transl Med (2014) 0.77
Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies. Blood (2016) 0.76
Advances in Immunotherapy for Glioblastoma Multiforme. J Immunol Res (2017) 0.75
Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy. Oncotarget (2016) 0.75
Role of heterogeneous cell population on modulation of dendritic cell phenotype and activation of CD8 T cells for use in cell-based immunotherapies. Cell Immunol (2016) 0.75
Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol (2017) 0.75
Dendritic cell control of immune responses. Front Immunol (2015) 0.75
Mitochondrion: A Promising Target for Nanoparticle-Based Vaccine Delivery Systems. Vaccines (Basel) (2016) 0.75
Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses. Oncoimmunology (2016) 0.75
Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol Res (2017) 0.75
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med (1973) 13.88
Proliferating dendritic cell progenitors in human blood. J Exp Med (1994) 7.67
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
Cancer immunology. N Engl J Med (2008) 5.22
Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med (1992) 5.03
Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med (1996) 4.15
A prescription for human immunology. Immunity (2008) 4.09
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature (2005) 3.81
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol (2011) 3.41
Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res (2001) 3.01
alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res (2004) 3.00
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32
Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 2.29
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A (2010) 1.84
Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res (2003) 1.83
Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res (2013) 1.75
Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine (2007) 1.75
T cell assays and MIATA: the essential minimum for maximum impact. Immunity (2012) 1.74
Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res (1999) 1.73
Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest (1990) 1.72
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res (2006) 1.67
Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care (2011) 1.65
Type I interferon response and innate immune sensing of cancer. Trends Immunol (2012) 1.59
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol (2006) 1.49
MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) (2012) 1.39
Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother (2008) 1.37
Dendritic cells and immunity against cancer. J Intern Med (2011) 1.32
Functional assessment of human dendritic cells labeled for in vivo (19)F magnetic resonance imaging cell tracking. Cytotherapy (2010) 1.23
Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates. Am J Transplant (2013) 1.22
Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci U S A (1995) 1.20
Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother (2006) 1.19
Development of a potency assay for human dendritic cells: IL-12p70 production. J Immunother (2008) 1.14
Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med (2010) 1.06
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res (2013) 1.01
Superior efficacy of tumor cell vaccines grown in physiologic oxygen. Clin Cancer Res (2010) 0.98
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Ann Oncol (2006) 0.96
Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy. Melanoma Res (2006) 0.91
Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res (2006) 0.88
Biodistribution of radiolabelled human dendritic cells injected by various routes. Eur J Nucl Med Mol Imaging (2005) 0.86
Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunol Res (2011) 0.86
Quality controls in cellular immunotherapies: rapid assessment of clinical grade dendritic cells by gene expression profiling. Mol Ther (2012) 0.85
Fast generation of dendritic cells. Cell Immunol (2009) 0.84
Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen. Oncoimmunology (2012) 0.84